Private: Gallery Post #1

06

Jan2020

PMPRB Consultation Update and Patentee Webinar

Recently, the deadline for providing written submissions on the PMPRB’s proposed new Guidelines was extended until January 31, 2020. As part of the ongoing consultation process, the PMPRB has reserved three days in January for bilateral meetings with individual patentees: January 8, 9, and 10, 2020. Meetings will be scheduled on ... Read More

10

Dec2019

Status Summary of Innovative Medicine pCPA Negotiations as of November 30, 2019

Each month the pCPA issues an update on the previous month’s negotiation activity. Below, you will find an overview of the new pCPA activity along with PDCI insights into recent developments for your interest.             ... Read More

27

Nov2019

CADTH Releases Pharmaceutical Reviews Update – Issue 11

CADTH’s Pharmaceutical Reviews Updates are used to communicate new CDR and pCODR drug review processes updates to the public. PDCI has outlined below the key highlights from the most recent update. For more information on this review, please consult the CADTH website. This CADTH update primarily ... Read More

26

Nov2019

PDCI Market Access: PMPRB Reforms Briefing and Strategy Sessions (Toronto and Montreal)

REGISTRATION IS OPEN! Learn how the new PMPRB amendments and guidelines will affect your pharmaceutical pricing, negotiations and reimbursement Join PDCI Market Access Inc., Canada’s leading pricing and reimbursement consultancy, for industry-only sessions on the pricing guidelines, led by senior members ... Read More

22

Nov2019

Status Summary of Innovative Medicine pCPA Negotiations as of October 31, 2019

Each month the pCPA issues an update on the previous month’s negotiation activity. Below, you will find an overview of the new pCPA activity along with PDCI insights into recent developments for your interest. Summary of New pCPA Activity Since ... Read More

24

Oct2019

STATUS SUMMARY OF INNOVATIVE MEDICINE pCPA NEGOTIATIONS AS OF SEPTEMBER 30, 2019

Each month the pCPA issues an update on the previous month’s negotiation activity. Below, you will find an overview of the new pCPA activity along with PDCI insights into recent developments for your interest.  SUMMARY OF NEW PCPA ACTIVITY SINCE AUGUST ... Read More

07

Oct2019

PDCI Response to 2019 CADTH Consultations

In July 2019, CADTH announced a new round of public consultations on its Pharmaceutical Review Programs. CADTH’s proposed changes would affect how it manages, reviews and reconsiders information submitted by pharmaceutical manufacturers through its Common Drug Review. Stakeholders were invited to submit feedback on three consultations: Proposal to Enhance ... Read More

30

Aug2019

CADTH Releases Pharmaceutical Reviews Update 10

CADTH’s Pharmaceutical Reviews Updates are used to communicate new CDR and pCODR drug review processes updates to the public. PDCI has outlined below the key highlights from the most recent update. For more information on this review, please consult the CADTH website. CADTH has extended the ... Read More

27

Aug2019

UPCOMING WEBINAR SEPTEMBER 4: 2019 PMPRB Regulation Amendments and Implications

PDCI and 3Sixty Public Affairs invites its industry clients, partners and colleagues to participate in a webinar on September 4, 2019 between 2:00pm to 3:00pm. This important session will cover the PMPRB price regulatory amendments and share insights on their implications for pharmaceutical market access. The session will provide an overview of ... Read More

19

Aug2019

HDAP 2020 Meeting Dates Released

The PMPRB has announced the 2020 meeting dates to the Human Drug Advisory Panel (HDAP)’s , releasing a total of four (4) dates, as per previous years. This corrected version of TargetPharma makes a distinction between the deadline for submitting the Product Monograph and the deadline for the Patentee's submission.... Read More